Understanding how cancer cells adapt to stress
Attacking stress tolerance in cancer
This study is looking at how cancer cells handle tough situations, like not getting enough oxygen or nutrients, and it focuses on a protein that helps them survive treatment; by understanding this better, the researchers hope to find new ways to make cancer treatments more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10918081 on NIH RePORTER |
What this research studies
This research investigates how cancer cells respond to various stressors, such as low oxygen levels and nutrient shortages, which can occur during treatment. It focuses on a specific protein, integrin αvβ3, that helps tumor cells survive and become resistant to therapies. By studying how this protein is activated in different types of tumors, the research aims to uncover new ways to target and disrupt these survival mechanisms. The ultimate goal is to develop therapies that can prevent cancer progression and improve treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may be experiencing treatment resistance.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not express integrin αvβ3 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that make cancer cells more vulnerable to existing therapies, potentially improving patient survival rates.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer cells, indicating that this approach has potential for success.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Cheresh, David a — University of California, San Diego
- Study coordinator: Cheresh, David a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.